Table 1.
Prevalence of CLDN18.2-positive gastric or GEJ cancer and the clinicopathological features.
| Design/cohort | Screening test in SPOTLIGHT and GLOW | Kubota et al. 57 | Pellino et al. 34 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Design | Screening test | Retrospective study | Retrospective study | |||||||||
| Race (country) | Various | Asian (Japan) | Caucasian (Italy) | |||||||||
| Stage | IV | IV | I–IV | |||||||||
| N | 4507 | 408 | 350 | |||||||||
| Feature/biomarker | CLDN18.2+ | CLDN18.2− | p | CLDN18.2+ | CLDN18.2− | p | CLDN18.2+ | CLDN18.2− | p | |||
| Overall | 1730 (38.4%) | 2777 (61.6%) | 98 (24.0%) | 310 (76.0%) | 117 (33.4%) | 223 (66.6%) | ||||||
| Male | 1093 (36.2%) | 1924 (63.8%) | <0.0001 | 66 (23.5%) | 215 (76.5%) | 0.709 | 80 (25.2%) | 238 (74.8%) | 0.1214 | |||
| Female | 637 (42.8%) | 853 (57.2%) | 32 (25.2%) | 95 (74.8%) | 37 (28.0%) | 95 (72.0%) | ||||||
| Age | ⩽65 | 1136 (40.9%) | 1639 (59.1%) | <0.0001 | <65 | 45 (26.6%) | 124 (73.4%) | 0.347 | <70 | 83 (39.7%) | 126 (60.3%) | 0.0035 |
| >65 | 594 (34.3%) | 1138 (34.3%) | ⩾65 | 53 (22.2%) | 186 (77.8%) | >70 | 34 (24.1%) | 107 (75.9%) | ||||
| Gastric | 1341 (39.9%) | 2016 (60.1%) | 0.1846 | 85 (23.4%) | 278 (76.6%) | 0.459 | 90 (32.1%) | 190 (67.9%) | 0.3799 | |||
| GEJ | 338 (37.5%) | 563 (62.5%) | 13 (28.9%) | 32 (71.1%) | 27 (38.6%) | 43 (61.4%) | ||||||
| Lauren classification | ||||||||||||
| Diffuse | 553 (48.3%) | 592 (51.7%) | 0.0002 | 47 (25.5%) | 137 (74.5%) | 0.561 | 47 (40.2%) | 70 (59.8%) | 0.076 | |||
| Intestinal | 308 (38.8%) | 486 (61.2%) | 51 (22.8%) | 173 (77.2%) | 54 (29.0%) | 132 (71.0%) | 0.0813 | |||||
| Mixed | 134 (42.9%) | 178 (57.1%) | 14 (35.9%) | 25 (64.1%) | 0.8676 | |||||||
| Other | 252 (37.2%) | 425 (62.8%) | ||||||||||
| Unknown | 412 (35.0%) | 765 (65.0%) | ||||||||||
| Macroscopic classification | 0.019 | |||||||||||
| Type4 | NA | NA | NA | 28 (34.6%) | 53 (65.4%) | 0.019 | NA | NA | ||||
| Non-Type4 | NA | NA | 70 (21.4%) | 257 (78.6%) | NA | NA | ||||||
| HER2+ | 162 (20.2%) | 640 (79.8%) | NE | 15 (25.9%) | 43 (74.1%) | 0.741 | 17 (32.7%) | 35 (67.3%) | 1 | |||
| HER2− | 1568 (42.3%) | 2137 (57.7%) | 83 (23.7%) | 267 (76.3%) | 100 (33.6%) | 198 (66.4%) | ||||||
| dMMR/MSI-H | NA | NA | NA | 5 (20.8%) | 19 (79.2%) | 0.81 | 15 (23.1%) | 50 (76.9%) | 0.2424 | |||
| EBV+ | NA | NA | NA | 4 (26.7%) | 11 (73.3%) | 0.763 | 7 (87.5%) | 1 (12.5%) | 0.0024 | |||
| CPS < 5 | 495/599 (82.6%*) | NA | NA | 54/93 (58.1%*) | 142/293 (48.5%*) | 0.122 | 21 (10.3%*) | 183 (89.7%*) | 0.529 | |||
| CPS ⩾ 5 | 104/599 (17.4%*) | 39/93 (41.9%*) | 151/293 (51.5%*) | 96 (65.8%*) | 50 (34.2%*) | |||||||
| Clinical features of CLDN18.2+ GC/GEJC | Female, younger age, diffuse type | Type 4 | Younger age, higher stage (III–IV), peritoneal meta, fewer liver meta | |||||||||
| Survival impact on CLDN18.2+ | NA | Not associated | Not associated | |||||||||
| Reference | Shitara et al. 31 | Kubota et al. 57 | Pellino et al. 34 | |||||||||
*
Percentage in CLDN18.2 positive or CLDN18.2-negative group.
Abbreviations: meta, metastasis; GC, gastric cancer; GEJC, Gastro-Esophageal Junction Cancer ; NA, not available; NE, not evaluated.